fig2

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Figure 2. Best overall response and progression-free survival of patients stratified by treatment strategy after ICIs failure. (A) Best overall response of previous immunotherapy. (B) Progression-free survival of previous immunotherapy. (C) Best overall response of subsequent therapy. (D) Progression-free survival of subsequent therapy. (E) Overall survival of subsequent therapy. BOR: Best overall response; ICIs: immune checkpoint inhibitors; PR: partial response; SD: stable disease; PD: progressive disease.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/